The Atorvastatin Goal Achievement Across Risk Levels: (ATGOAL) study in Thailand
Deerochanawong, C.; Buranakitjaroen, P.; Nitiyanant, W.; Suwantamee, J.; Piamsomboon, C.; Vongthavaravat, V.; Suwanwela, N.Charnnarong.; Kosachunhanun, N.; Sukonthasarn, A.
Journal of the Medical Association of Thailand 90(1): 72-81
2007
ISSN/ISBN: 0125-2208 PMID: 17621736 Document Number: 2735
Objective: To evaluate the efficacy and safety of atorvastatin at the starting doses of 10, 20, 40 mg and evaluate the effectiveness of 1 step titrate up regimen.Material and Method: Two hundred and forty two subjects with dyslipidemia were enrolled and assigned the appropriate dose in relation to their individual cardiovascular risk status and baseline LDL-C levels. If the NCEP targets were not achieved, the doses were titrated up at week 4 and the primary efficacy was evaluated at week 8.Results: A majority of subjects (88.8%) achieved their LDL-C goals at week 8. Almost all of the subject LDLC levels reached their goals by week 2 and 4 (81.6% and 87.1%, respectively). Only 10.7% (n=25) required the sole titration. Each dose provided significant decreases in LDL-C (average 464%). Only 36 subjects experienced treatment related adverse events, the majority of these were in the high-risk group (n=22) with only one subject registering a serious adverse event.Conclusion: Atorvastatin is effective and safe for Thai patients with dyslipidemia. The appropriate starting dose has contributed in the achievement of cholesterol reduction.
Document emailed within 1 workday
